Abstract
Background Vaccines for COVID-19 represent a breakthrough in the fight against the pandemic. However, worries about adverse effects led to vaccine hesitancy in some people. On the other hand, as COVID-19 may be associated with various sequelae, the vaccine may protect against these diseases.
Methods We leveraged a large prospective cohort, the UK-Biobank(UKBB), and studied associations of at least one dose of COVID-19 vaccination(BioNTech-BNT162b2 or Oxford-AstraZeneca-ChAdOx1) with hospitalization from cardiovascular and other diseases (N=393,544; median follow-up of 54 days in vaccinated). Multivariable Cox and Poisson regression was conducted controlling for main confounders. Besides all hospitalizations, we also conducted separate analysis for new-onset and recurrent cases. We also performed other sensitivity analyses, including adjustment for prior event rate ratio (PERR) to reduce residual confounding.
Results We observed that COVID-19 vaccination(at least one dose) was associated with lower risks of hospitalizations from stroke (hazard ratio[HR]=0.178, 95% CI: 0.127-0.250, p=1.50e-23), VTE (HR=0.426, 95% CI: 0.270-0.673, p=2.51e-4), dementia (HR=0.114, 95% CI 0.060-0.216; p=2.24e-11), non-COVID-19 pneumonia (NCP) (HR=0.108, 95% CI 0.0.080-0.145; p=2.20e-49), CAD (HR=0.563, 95% CI: 0.416-0.762; p=2.05e-4), COPD (HR=0.212, 95% CI 0.126-0.357; p=4.92e-9), T2DM (HR= 0.216, 95% CI: 0.096 - 0.486, p=2.12e-4), heart failure (HR=0.174, 95% CI, 0.118-0.256, p=1.34e-18) and renal failure (HR=0.415, 0.255-0.677, p=4.19e-4).
After adjusting for HRs of hospitalization between the two groups before the introduction of vaccination, COVID-19 vaccination was still significantly associated with reduced hazards of hospitalization due to CAD (HR=0.517, 95% CI: 0.327-0.817; p=4.70e-03), COPD (HR=0.317, 95% CI: 0.138-0.726; p=6.60e-03), dementia (HR=0.406, 95% CI: 0.180-0.919; p=3.06e-02), heart failure (HR=0.305, 95% CI: 0.179-0.519; p=1.18e-05), NCP (HR=0.191, 95% CI: 0.123-0.295; p=1.02e-13) and stroke (HR=0.222, 95% CI: 0.130-0.382; p=4.94e-08), although the estimated protective effects were weaker.
Conclusions Taken together, this study provides further support to the safety and benefits of COVID-19 vaccination, and such benefits may extend beyond reduction of infection risk or severity per se. As an observational study, causal relationship cannot be concluded and further studies are required to verify the findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported partially a National Natural Science Foundation China (NSFC) grant (81971706), the Lo Kwee Seong Biomedical Research Fund from The Chinese University of Hong Kong and the KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong, China.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank study has received ethical approval from the NHS National Research Ethics Service North West (16/NW/0274).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Qualified researchers may apply for access to the UK Biobank, which contains individual-level data. Summary results are presented in main and supplementary tables.